Content about Pharmaceutical sciences

November 12, 2012

The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.

TITUSVILLE, N.J. — The Food and Drug Administration has approved a new strength of a drug for HIV made by Johnson & Johnson, the drug maker said.

J&J subsidiary Janssen Therapeutics announced the approval of an 800-mg formulation of Prezista (darunavir) as a once-daily treatment for HIV. The drug is designed to be taken with food at the same time as ritonavir and in combination with other HIV drugs.

November 12, 2012

The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug for pulmonary arterial hypertension made by Watson Pharmaceuticals, the drug maker said Monday.

Watson said the FDA approved its sildenafil tablets in the 20 mg strength through a subsidiary. Watson said it would launch the drug "in the near future."

The drug is a generic version of Pfizer's Revatio tablets, which had sales of about $339 million during the 12-month period ended in September, according to IMS Health.

November 12, 2012

Drug maker Purdue Pharma and the National Community Pharmacists Association have introduced the latest version of a video designed to educate pharmacists and other pharmacy staff about pharmacy crime.

STAMFORD, Conn. — Drug maker Purdue Pharma and the National Community Pharmacists Association have introduced the latest version of a video designed to educate pharmacists and other pharmacy staff about pharmacy crime.

The video, part of RxPatrol, Purdue's broader initiative to combat pharmacy crime, launched on the initiative's website. Titled "RxPatrol Pharmacy Safety and Security," it is free of charge, and is part of the NCPA's Protect Your Pharmacy Now! initiative, which started in 2008.

November 12, 2012

The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

NEW YORK — The PBM division of CVS Caremark is hoping to get patients to use lower-cost drugs for certain conditions by removing higher-cost drugs from its formulary, according to published reports.

The Wall Street Journal reported that CVS Caremark would stop covering 17 drugs starting on Jan. 1, 2013, after removing 30 this year. The drugs include Abbott's Androgel (testosterone gel) for low testosterone, and Pfizer's drug Detrol LA (tolterodine tartrate) for overactive bladder.

November 9, 2012

Earlier this week, DSN reported that members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain 10 generic hypertension drugs from Walmart for a penny.

It's certainly good news for people with high blood pressure, but it also has big implications for the pharmacy retail industry.

Earlier this week, DSN reported that members of a prescription drug program offered by Humana to Medicare beneficiaries will soon be able to obtain 10 generic hypertension drugs from Walmart for a penny.

It's certainly good news for people with high blood pressure, but it also has big implications for the pharmacy retail industry.

November 9, 2012

CVS Caremark reported strong numbers on both the retail and PBM sides of its business — but the real bombshell for analysts on the call was the news that the company has raised its estimate on the number of Express Script patients that CVS feels it can keep from going back to Walgreens.

That's a big boast. But Rite Aid, too, likes its shot to keep the ESI customers who at one time frequented Walgreens' pharmacies to fill their prescriptions. And Walgreens, for its part, reminds analysts that there was a reason those ESI patients were filling their prescriptions in the first place. So the Chicago retailer is confident that they'll be able to entice many of their former patients to return to the pharmacy fold. But in the end, who's really going to capture that coveted ESI patient? Will they stay, or will they go?

November 8, 2012

The Food and Drug Administration has accepted an application from Merck for an experimental drug for insomnia, the drug maker said Thursday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted an application from Merck for an experimental drug for insomnia, the drug maker said Thursday.

Merck announced the the FDA's acceptance of its regulatory filing for suvorexant, which the FDA's Controlled Substances Staff will review while the agency is reviewing the application.

November 8, 2012

A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

EAST HANOVER, N.J. — A Food and Drug Administration expert panel has voted unanimously in favor of approval for a Novartis drug for a rare endocrine disorder.

November 8, 2012

Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running.

BRIDGEWATER, N.J. — Valeant Consumer Products recently announced that its line of Ocean Saline Nasal Sprays has been the most recommended by pharmacists for 15 years running. 

Ocean offers nonmedicated relief from dry and irritated nasal passages due to allergies, colds, flu, sinusitis and rhinitis. The nasal spray is gentle enough for infants and has three delivery options — standing the bottle upright delivers a spray; horizontally, a stream; and upside-down, a drop. 

November 7, 2012

The Food and Drug Administration on Monday issued a warning letter to The Avalon Effect, a company based in Franklin, Tenn., for its marketing of a light therapy product that claims to cure or treat symptoms of fungal meningitis, methicillin-resistant Staphylococcus aureus, concussions, Lyme disease and other diseases.

SILVER SPRING, Md. — The Food and Drug Administration on Monday issued a warning letter to The Avalon Effect, a company based in Franklin, Tenn., for its marketing of a light therapy product that claims to cure or treat symptoms of fungal meningitis, methicillin-resistant Staphylococcus aureus, concussions, Lyme disease and other diseases.

November 7, 2012

A new Walgreens study examining the impact of 90-day medication refills at community pharmacies compared to 30-day refills for Medicaid patients found that across four therapeutic categories, patients with 90-day refills had greater medication adherence and greater persistency, nominal wastage and more cost savings.

DEERFIELD, Ill. — A new Walgreens study examining the impact of 90-day medication refills at community pharmacies compared to 30-day refills for Medicaid patients found that across four therapeutic categories, patients with 90-day refills had greater medication adherence and greater persistency, nominal wastage and more cost savings. The study, titled "Medication Days’ Supply, Adherence, Wastage and Cost Among Chronic Patients in Medicaid," was published in Medicare & Medicaid Research Review and released Wednesday.

November 6, 2012

Pennsylvania Gov. Tom Corbett last week signed into law S.B. 201, a bill that takes critical steps toward leveling the playing field between large pharmacy benefit managers and the mail-order pharmacies they own and local, independent community pharmacies.

ALEXANDRIA, Va. — Pennsylvania Gov. Tom Corbett last week signed into law S.B. 201, a bill that takes critical steps toward leveling the playing field between large pharmacy benefit managers and the mail-order pharmacies they own and local, independent community pharmacies. The legislation was applauded by community pharmacists. 

November 6, 2012

Teva Pharmaceutical Industries has made a few new executive appointments, the drug maker said Tuesday.

JERUSALEM — Teva Pharmaceutical Industries has made some new executive appointments, the drug maker said Tuesday.

Teva promoted Allan Oberman, currently SVP North America generic pharmaceuticals, to president and CEO of Teva Americas Generics. In the new role, Oberman will report directly to Teva president and CEO Jeremy Levin and have continued responsibility for generics in the North American market and overall management of the company's Latin American businesses.

November 5, 2012

Industry leaders at an annual retail pharmacy conference in Canada got a look at a kiosk that allows patients to order prescription drugs through an Internet connection.

TORONTO — Industry leaders at an annual retail pharmacy conference in Canada got a look at a kiosk that allows patients to order prescription drugs through an Internet connection.

TCE Group announced the introduction of its Pharma Kiosk, or PK+ terminal at the annual meeting of the Canadian Association of Chain Drug Stores in Toronto.

November 5, 2012

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating internal blood clots, the company said.

RARITAN, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating internal blood clots, the company said.

J&J subsidiary Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) for treating deep-vein thrombosis and pulmonary embolism and to reduce the risk of recurrence of the clotting conditions after initial treatment.

The company said Xarelto was the first oral anticoagulant approved to treat DVT and PE without the need for injections or routine blood-monitoring.

November 5, 2012

The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain.

FDA approves cardiovascular drug

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for treating blood pressure and chest pain. Actavis announced the approval of diltiazem hydrochloride extended-release capsules.
The drug is a generic version of Valeant’s Tiazac. The branded drug and its generic equivalents had sales of about $76.3 million in 2011, according to IMS Health.



November 5, 2012

Pharmacy automation manufacturer Kirby Lester has launched a version of one of its tablet counters with streamlined verification software.

SUPPLIER NEWS — Pharmacy automation manufacturer Kirby Lester has launched a version of one of its tablet counters with streamlined verification software. The company announced the launch of KL1Plus, which it said combines the KL1 tablet counter with the updated software.


November 5, 2012

Improving medication adherence in specialty pharmacy could be equivalent to introducing a new blockbuster drug. That’s how Diplomat Specialty Pharmacy president and CEO Phil Hagerman put it at Drug Store News’ Specialty Pharmacy Roundtable two years ago. 


Improving medication adherence in specialty pharmacy could be equivalent to introducing a new blockbuster drug. That’s how Diplomat Specialty Pharmacy president and CEO Phil Hagerman put it at Drug Store News’ Specialty Pharmacy Roundtable two years ago. 


November 5, 2012

An interactive kiosk that allows customers to order prescription glasses and contact lenses online, a special shelf for diabetes products and a new interior design are among the newest features at Rite Aid’s newest version of its Wellness store in Lemoyne, Pa.

LEMOYNE, Pa. — An interactive kiosk that allows customers to order prescription glasses and contact lenses online, a special shelf for diabetes products and a new interior design are among the newest features at Rite Aid’s newest version of its Wellness store in Lemoyne, Pa. A path of wooden flooring leads directly to the store’s pharmacy, whose immediate surrounding area has been cleared of merchandise to give it a more open look.

November 5, 2012

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis.

In what its president and CEO called a “significant milestone,” Watson Pharmaceuticals announced last month that the U.S. Federal Trade Commission and European Commission had approved its acquisition of Swiss generic drug maker Actavis. Watson announced the $5.6 billion acquisition of Actavis in April, a deal that is expected to make Watson the third-largest generic drug maker in the world, after Teva Pharmaceutical Industries and Mylan.

November 2, 2012

Given the extent of the meningitis outbreak linked to a compounding pharmacy in Massachusetts, new regulations for such pharmacies might be a good idea, but how to implement them remains uncertain.

(THE NEWS: Meningitis outbreak linked to compounding pharmacy spawns new proposed legislation. Click here to read the story.)

WHAT IT MEANS AND WHY IT'S IMPORTANT — Given the extent of the meningitis outbreak linked to a compounding pharmacy in Massachusetts, new regulations for such pharmacies might be a good idea, but how to implement them remains uncertain.

(THE NEWS: Meningitis outbreak linked to compounding pharmacy spawns new proposed legislation. Click here to read the story.)

November 2, 2012

Rep. Edward Markey, D-Mass., on Thursday announced plans to introduce legislation that would strengthen federal regulations of compounding pharmacies.

ALEXANDRIA, Va. — Rep. Edward Markey, D-Mass., on Thursday announced plans to introduce legislation that would strengthen federal regulations of compounding pharmacies. The legislation is borne out of the recent meningitis outbreak linked to the New England Compounding Center, which is located in Markey's district, that has drawn much criticism on how regulators oversee compounding pharmacies.

November 1, 2012

Some generic drugs may come under more scrutiny from the Food and Drug Administration amid reports that the generic version of a treatment for depression didn't work as well as the branded version, according to published reports.

NEW YORK – Some generic drugs may come under more scrutiny from the Food and Drug Administration amid reports that the generic version of a treatment for depression didn't work as well as the branded version, according to published reports.

November 1, 2012

Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

PARSIPPANY, N.J. – Watson Pharmaceuticals is changing its name to Actavis following its acquisition of the Swiss drug maker, Watson said.

 

Watson, whose $5.6 billion acquisition of Actavis received approval from the Federal Trade Commission earlier this month, said it would adopt the new name starting in 2013, with plans to start a multi-year rebranding campaign and trade under a new symbol on the New York Stock Exchange.

 

October 31, 2012

Watson Pharmaceuticals on Wednesday announced the sale of its Rugby over-the-counter business to the Harvard Drug Group — a distributor and provider of private-label OTCs and generic prescription products under the Major Pharmaceuticals brand — for approximately $117 million.

PARSIPPANY, N.J. — Watson Pharmaceuticals on Wednesday announced the sale of its Rugby over-the-counter business to the Harvard Drug Group — a distributor and provider of private-label OTCs and generic prescription products under the Major Pharmaceuticals brand — for approximately $117 million.  

"I am confident that Major, with its leadership position as a marketer of OTC products, will be more strategically positioned to maximize the value of the long-known and respected Rugby name," stated Paul Bisaro, president and CEO of Watson.